242 related articles for article (PubMed ID: 27395386)
1. Refractory chronic migraine: is drug withdrawal necessary before starting a therapy with onabotulinum toxin type A?
Butera C; Colombo B; Bianchi F; Cursi M; Messina R; Amadio S; Guerriero R; Comi G; Del Carro U
Neurol Sci; 2016 Oct; 37(10):1701-6. PubMed ID: 27395386
[TBL] [Abstract][Full Text] [Related]
2. Botulinum toxin type A and acute drug costs in migraine with triptan overuse.
Christie SN; Giammarco R; Gawel M; Mackie G; Gladstone J; Becker WJ
Can J Neurol Sci; 2010 Sep; 37(5):588-94. PubMed ID: 21059503
[TBL] [Abstract][Full Text] [Related]
3. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
Silberstein SD; Blumenfeld AM; Cady RK; Turner IM; Lipton RB; Diener HC; Aurora SK; Sirimanne M; DeGryse RE; Turkel CC; Dodick DW
J Neurol Sci; 2013 Aug; 331(1-2):48-56. PubMed ID: 23790235
[TBL] [Abstract][Full Text] [Related]
4. The use of onabotulinum toxin A (Botox(®)) in the treatment of chronic migraine at the Parma Headache Centre: a prospective observational study.
Russo M; Manzoni GC; Taga A; Genovese A; Veronesi L; Pasquarella C; Sansebastiano GE; Torelli P
Neurol Sci; 2016 Jul; 37(7):1127-31. PubMed ID: 27048312
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study.
Sandrini G; Perrotta A; Tassorelli C; Torelli P; Brighina F; Sances G; Nappi G
J Headache Pain; 2011 Aug; 12(4):427-33. PubMed ID: 21499747
[TBL] [Abstract][Full Text] [Related]
6. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
7. Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting.
Santoro A; Fontana A; Miscio AM; Zarrelli MM; Copetti M; Leone MA
Neurol Sci; 2017 Oct; 38(10):1779-1789. PubMed ID: 28726049
[TBL] [Abstract][Full Text] [Related]
8. Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN
Ion I; Renard D; Le Floch A; De Verdal M; Bouly S; Wacongne A; Lozza A; Castelnovo G
Toxins (Basel); 2018 Jun; 10(6):. PubMed ID: 29857565
[TBL] [Abstract][Full Text] [Related]
9. Humanistic, utilization, and cost outcomes associated with the use of botulinum toxin for treatment of refractory migraine headaches in a managed care organization.
Mitchell MP; Schaecher K; Cannon HE; Speckman M
J Manag Care Pharm; 2008 Jun; 14(5):442-50. PubMed ID: 18597573
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin type A in refractory chronic migraine: an open-label trial.
Menezes C; Rodrigues B; Magalhães E; Melo A
Arq Neuropsiquiatr; 2007 Sep; 65(3A):596-8. PubMed ID: 17876397
[TBL] [Abstract][Full Text] [Related]
11. [Botulinum toxin A in chronic refractory migraine: premarketing experience].
Álvaro-González LC; Fernández-García JM; Aranzábal-Alustiza I; Castillo-Calvo B; Iriondo-Etxenagusia I; Rodríguez-Antigüedad A
Rev Neurol; 2012 Oct; 55(7):385-91. PubMed ID: 23011856
[TBL] [Abstract][Full Text] [Related]
12. Onabotulinum toxin A (Botox) for chronic migraine treatment: an Italian experience.
Grazzi L; Usai S
Neurol Sci; 2015 May; 36 Suppl 1():33-5. PubMed ID: 26017508
[TBL] [Abstract][Full Text] [Related]
13. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness, Safety, and Health-Related Quality of Life of Chronic Migraine Patients Treated with Onabotulinum Toxin A.
Beckmann Y; Çetin Üncü F; Kurt İncesu T; Türe S
Eur Neurol; 2020; 83(5):517-522. PubMed ID: 32966982
[TBL] [Abstract][Full Text] [Related]
15. Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse.
Freitag FG; Diamond S; Diamond M; Urban G
Headache; 2008 Feb; 48(2):201-9. PubMed ID: 18042229
[TBL] [Abstract][Full Text] [Related]
16. OnabotulinumtoxinA (BOTOX®): a review of its use in the prophylaxis of headaches in adults with chronic migraine.
Frampton JE
Drugs; 2012 Apr; 72(6):825-45. PubMed ID: 22468643
[TBL] [Abstract][Full Text] [Related]
17. Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study.
Young WB; Ivan Lopez J; Rothrock JF; Orejudos A; Manack Adams A; Lipton RB; Blumenfeld AM
J Headache Pain; 2019 Feb; 20(1):12. PubMed ID: 30709333
[TBL] [Abstract][Full Text] [Related]
18. Botulinum Toxin versus Placebo: A Meta-Analysis of Prophylactic Treatment for Migraine.
Bruloy E; Sinna R; Grolleau JL; Bout-Roumazeilles A; Berard E; Chaput B
Plast Reconstr Surg; 2019 Jan; 143(1):239-250. PubMed ID: 30589800
[TBL] [Abstract][Full Text] [Related]
19. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.
Aurora SK; Dodick DW; Turkel CC; DeGryse RE; Silberstein SD; Lipton RB; Diener HC; Brin MF;
Cephalalgia; 2010 Jul; 30(7):793-803. PubMed ID: 20647170
[TBL] [Abstract][Full Text] [Related]
20. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.
Lipton RB; Varon SF; Grosberg B; McAllister PJ; Freitag F; Aurora SK; Dodick DW; Silberstein SD; Diener HC; DeGryse RE; Nolan ME; Turkel CC
Neurology; 2011 Oct; 77(15):1465-72. PubMed ID: 21956721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]